Edition:
United Kingdom

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

1.67USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.67
Open
$1.66
Day's High
$1.68
Day's Low
$1.66
Volume
10,825
Avg. Vol
105,223
52-wk High
$2.58
52-wk Low
$0.90

Select another date:

Mon, Apr 9 2018

BRIEF-Second Sight Medical Products Says Robert Greenberg's Resignation "Was An Outgrowth Of A Disagreement Over His Reporting Relationship" With Co

* FORMER CHAIMAN ROBERT GREENBERG'S RESIGNATION "WAS AN OUTGROWTH OF A DISAGREEMENT OVER HIS REPORTING RELATIONSHIP" WITH CO

BRIEF-Second Sight Appoints John Blake Chief Financial Officer

* SECOND SIGHT APPOINTS JOHN T. BLAKE CHIEF FINANCIAL OFFICER

BRIEF-Second Sight Appoints Gregg Williams As Chairman Of The Board Of Directors

* SECOND SIGHT APPOINTS GREGG WILLIAMS AS CHAIRMAN OF THE BOARD OF DIRECTORS

BRIEF-Second Sight Q4 Loss Per Share $0.13

* SECOND SIGHT REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Second Sight Announces Market Entry Into Singapore With First Implant Of Argus II Retinal Prosthesis System

* SECOND SIGHT ANNOUNCES MARKET ENTRY INTO SINGAPORE WITH FIRST IMPLANT OF ARGUS II RETINAL PROSTHESIS SYSTEM Source text for Eikon: Further company coverage:

BRIEF-SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM

* SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM

BRIEF-Second Sight Medical Products reports Q3 loss per share $0.12

* Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11 Source text for Eikon: Further company coverage:

BRIEF-Second Sight receives FDA approval to begin first Orion human clinical study

* Second Sight receives full FDA approval to begin first Orion human clinical study

BRIEF-Second Sight Medical Products files for mixed shelf of upto $100 mln‍​

* Second Sight Medical Products Inc files for mixed shelf of upto $100 million - sec filing‍​ Source text : http://bit.ly/2gXz4DE Further company coverage:

Select another date: